Survival of infants born with esophageal atresia among 24 international birth defects surveillance programs. Issue 12 (18th March 2021)

• Record Type: Journal Article
• Authors: Bell, Jane C.; Baynam, Gareth; Bergman, Jorieke E. H.; Bermejo‐Sánchez, Eva; Botto, Lorenzo D.; Canfield, Mark A.; Dastgiri, Saeed; Gatt, Miriam; Groisman, Boris; Hurtado‐Villa, Paula; Kallen, Karin; Khoshnood, Babak; Konrad, Victoria; Landau, Danielle; Lopez‐Camelo, Jorge S.; Martinez, Laura; Morgan, Margery; Mutchinick, Osvaldo M.; Nance, Amy E.; Nembhard, Wendy; Pierini, Anna; Rissmann, Anke; Shan, Xiaoyi; Sipek, Antonin; Szabova, Elena; Tagliabue, Giovanna; Yevtushok, Lyubov S.; Zarante, Ignacio; Nassar, Natasha
• Is Part Of: Birth defects research. Volume 113:Issue 12(2021)
• Page Start: 945
• Page End: 957
• Publication Date: 2021-03-18
• Subjects: congenital anomalies -- esophageal atresia -- infant -- mortality -- survival; Teratology -- Periodicals; Abnormalities, Human -- Periodicals; Congenital Abnormalities; Embryo, Mammalian -- abnormalities; Teratology; Abnormalities, Human; Teratology; Periodicals; Periodicals; 616.043
• DOI: 10.1002/bdr2.1891
• Languages: English
• ISSNs: 2472-1727

Abstract

Abstract: Background: Esophageal atresia (EA) affects around 2.3–2.6 per 10, 000 births world‐wide. Infants born with this condition require surgical correction soon after birth. Most survival studies of infants with EA are locally or regionally based. We aimed to describe survival across multiple world regions. Methods: We included infants diagnosed with EA between 1980 and 2015 from 24 birth defects surveillance programs that are members of the International Clearinghouse for Birth Defects Surveillance and Research. We calculated survival as the proportion of liveborn infants alive at 1 month, 1‐ and 5‐years, among all infants with EA, those with isolated EA, those with EA and additional anomalies or EA and a chromosomal anomaly or genetic syndrome. We also investigated trends in survival over the decades, 1980s–2010s. Results: We included 6, 466 liveborn infants with EA. Survival was 89.4% (95% CI 88.1–90.5) at 1‐month, 84.5% (95% CI 83.0–85.9) at 1‐year and 82.7% (95% CI 81.2–84.2) at 5‐years. One‐month survival for infants with isolated EA (97.1%) was higher than for infants with additional anomalies (89.7%) or infants with chromosomal or genetic syndrome diagnoses (57.3%) with little change at 1‐ and 5‐years. Survival at 1 month improved from the 1980s to the 2010s, by 6.5% for infants with isolated EA and by 21.5% for infants with EA and additional anomalies. Conclusions: Almost all infants with isolated EA survived to 5 years. Mortality was higher for infants with EA and an additional anomaly, including chromosomal or genetic syndromes. Survival improved from the 1980s, particularly for those with additional anomalies.